Abstract
In this essay the authors discuss how the development of remdesivir, one of the first drugs authorized for the treatment of COVID-19, demonstrates the United States’ complex system of collaborative public/private biopharmaceutical research, a system that produces a steady stream of innovations, but may not give adequate recognition (and rights) to the public contribution to those innovations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
